Filter by

  • REACH Clinical Trial

    Diagnosis Requirements: Mild cognitive impairment or Alzheimer’s
    Age Eligibility: Ages 55 to 89 years

    The REACH clinical trial is 1 of 16 trials worldwide offering promising therapies for Alzheimer’s disease and dementia funded by the Alzheimer’s Association’s Part the Cloud global research grant program and Bill Gates. The trial will evaluate the use of Rapamycin to slow progression of amnestic mild cognitive impairment and early-stage Alzheimer’s. It will also collect vital information on Alzheimer’s markers and relevant outcomes for future clinical trials.

  • ART-AD Study

    Diagnosis Requirements: Alzheimer's disease
    Age Eligibility: Ages 50 to 80 years

    A new approach to dementia treatment- targeting the proteins connected to memory loss. Patients will receive 3TC, an FDA-approved drug commonly prescribed for HIV and Hepatitis B. Research shows that 3TC slows the disease mechanisms present in the early phases of Alzheimer’s disease.

  • AHEAD 3-45 Study

    Diagnosis Requirements: None
    Age Eligibility: Ages 55 to 80 years

    This study reviews a new treatment to prevent memory decline and slow the earliest symptoms of Alzheimer’s disease.

  • CARPE DIEM Study: Cognition, Age and Rapamycin Effectiveness-Downregulation of the mTor Pathway

    Diagnosis Requirements: Mild Cognitive Impairment or Early Stages of Alzheimer’s Disease
    Age Eligibility: Ages 55 to 85 years

    The purpose of this study is to evaluate if if the drug, Rapamycin, will reach the brain and effectively treat symptoms of Alzheimer’s disease and mild cognitive impairment using cerebrospinal fluid.

  • SIESTA Study: Sleep Issues – Efficacy and Sensitivity of Technological Assessments

    Diagnosis Requirements: Parkinson's Disease
    Age Eligibility: Open

    To provide easier, convenient testing in the future, this study will evaluate if at-home devices, like the FitBit, can detect these sleep disturbances in Parkinson’s with similar accuracy as a clinic-based sleep study.

  • Heart Function and Brain Health Study

    Diagnosis Requirements: Normal Heart Function or Diastolic Dysfunction
    Age Eligibility: Ages 60 years or older

    The purpose of this clinical trial is to study heart function in relation to brain health.

  • MIND Study: Memory Improvement Through Nicotine Dosing

    Diagnosis Requirements: None
    Age Eligibility: Ages 55 years or older

    The purpose of this study is to determine whether nicotine (in patch form) improves memory and functioning in adults diagnosed with mild cognitive impairment.

  • PEACE-AD Trial

    Diagnosis Requirements: Alzheimer's disease
    Age Eligibility:

    Open

    The trial will evaluate Prazosin, an FDA-approved drug, as treatment for people with severe agitation/disruptive behavior in Alzheimer’s disease.

  • 7T MRI Study of How COVID-19 Affects the Brain

    Diagnosis Requirements: None
    Age Eligibility:

    45 to 80 years

    Studying COVID-19’s long-term neurological and psychological impacts.

  • DiverseVCID: Diverse Vascular Contributions to Cognitive Impairment and Dementia

    Diagnosis Requirements: No
    Age Eligibility:

    Between the ages of 65 and 90 years

    The results of this study will be used to develop and validate a predictive risk model to inform future care.

  • SToMP-AD: Senolytic Therapy for Alzheimer’s Disease

    Diagnosis Requirements: Mild cognitive impairment or early Alzheimer’s with elevated tau protein in cerebrospinal fluid
    Age Eligibility:

    Must be at least 60 years old and have a legally authorized representative to attend all study visits.

    A treatment to remove dysregulated cells found in mild cognitive impairment and Alzheimer’s disease.

  • Compadre CART

    Diagnosis Requirements: No
    Age Eligibility:

    Age 62 or older, identify as Mexican American and has reliable broadband internet connection.

    To learn more about why dementia is disproportionately affecting Hispanics, our researchers are recruiting volunteers to learn how to better serve this underrepresented population.